Vaxine

Executive Summary

Vaxine is an Australian biotechnology company pioneering AI-driven vaccine design and its proprietary Advax™ delta-inulin adjuvant platform. The company's technology addresses a broad range of infectious diseases, including COVID-19, influenza, RSV, hepatitis B, malaria, Ebola, and tuberculosis, as well as oncology through targeted TLR-agonist immunotherapies. Founded in 2020 and based in Adelaide, Vaxine has raised $60 million and operates at the commercial stage, despite currently having no approved products on the market. Its Advax adjuvant has demonstrated potential to enhance vaccine efficacy and durability, positioning the company as a key player in next-generation vaccine and immunotherapy development. With a strong intellectual property portfolio and AI capabilities, Vaxine aims to accelerate the creation of effective vaccines and treatments for global health challenges. Vaxine's near-term outlook hinges on advancing its lead vaccine candidates through clinical trials and securing strategic partnerships for its adjuvant platform. The company's COVID-19 vaccine candidate, utilizing Advax, is in late-stage development and could deliver pivotal data that supports regulatory approvals. Additionally, Vaxine is exploring oncology applications, with early-stage programs targeting solid tumors. While the company has not yet achieved commercial revenues, its innovative technology and pipeline breadth provide significant upside potential. However, risks include clinical trial setbacks, regulatory hurdles, and competition from established vaccine developers. Overall, Vaxine represents a high-risk, high-reward opportunity in the biotechnology space, with catalysts expected over the next 12–18 months.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 COVID-19 vaccine efficacy data readout70% success
• Q2 2026Advax adjuvant licensing agreement with major pharma80% success
• Q3 2026Phase 1/2 interim data for TLR-agonist cancer immunotherapy60% success